Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 14/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241111 | 0.91 | BACE1 (0.62) | BACE1 | |
| Trifluoroacetic Acid SCHEMBL5005126 | 0.88 | BACE1 (0.57) | BACE1LMNAGRM2GRM3 | |
| SCHEMBL5028541 | 0.84 | BACE1 (0.56) | BACE1LMNA | |
| Trifluoroacetic Acid SCHEMBL4995659 | 0.84 | BACE1 (0.53) | BACE1 | |
| Trifluoroacetic Acid SCHEMBL4997227 | 0.82 | BACE1 (0.57) | BACE1GRM2GRM3 | |
| Trifluoroacetic Acid SCHEMBL5001506 | 0.81 | BACE1 (0.52) | BACE1LMNA | |
| Trifluoroacetic Acid SCHEMBL5007687 | 0.81 | BACE1 (0.57) | BACE1LMNA | |
| Trifluoroacetic Acid SCHEMBL5001827 | 0.80 | BACE1 (0.60) | BACE1 | |
| Trifluoroacetic Acid SCHEMBL5001583 | 0.80 | BACE1 (0.54) | BACE1LMNA | |
| SCHEMBL8241119 | 0.79 | BACE1 (0.49) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | claimed |
| EP-1957462-A2 | NOVEL 2-AMINO-HETEROCYCLES UDEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | Astra Zeneca AB (SE) | 2008-08-20 | — | — | EP | claimed |
| WO-2007058583-A2 | NOVEL 2-AMINO-HETEROCYCLES USEFUL IN THE TREATMENT OF ABETA-RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-05-24 | — | — | WO | claimed |
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | ASTRAZENECA AB (SE) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293709-A1 | Novel 2-Amino-Heterocycles Useful in the Treatment of Abeta-Related Pathologies | PSEN2, APP, PSEN1 | BACE1 4/4885LMNA 1489/4885GRM2 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.